Production (Stage)
Neumora Therapeutics, Inc.
NMRA
$1.02
$0.209925.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -258.06M | -243.79M | -293.70M | -274.18M | -254.02M |
| Total Depreciation and Amortization | 630.00K | 631.00K | 640.00K | 657.00K | 668.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.48M | 37.58M | 98.14M | 94.94M | 85.78M |
| Change in Net Operating Assets | 18.52M | 22.64M | 10.88M | -19.75M | -5.62M |
| Cash from Operations | -199.43M | -182.94M | -184.04M | -198.33M | -173.19M |
| Capital Expenditure | 775.00K | 0.00 | -819.00K | -856.00K | -856.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 122.83M | -70.56M | 42.74M | -90.40M | -87.58M |
| Cash from Investing | 123.60M | -70.56M | 41.92M | -91.25M | -88.43M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.76M | 21.60M | 6.59M | 239.72M | 237.47M |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -1.05M | -3.68M | -3.79M |
| Cash from Financing | 19.76M | 21.60M | 5.55M | 236.04M | 233.68M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.07M | -231.89M | -136.57M | -53.54M | -27.94M |